Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul B Mullan

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Oncogene|June 9, 2005
The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-gamma-mediated apoptosisPaul B Mullan, Alison M Hosey, Niamh E Buckley, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2019
Identification and SAR exploration of a novel series of Legumain inhibitorsSharon L Eddie, Aaron Gregson, Emma Graham, et al.
Molecular Cancer Research : MCR|March 22, 2007
BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNsNiamh E Buckley, Alison M Hosey, Julia J Gorski, et al.
Cancer Research|March 11, 2010
BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcriptionMary T Harte, Garrett J O'Brien, Niamh M Ryan, et al.
Scientific Reports|March 22, 2016
Quantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatmentNiamh E Buckley, Claire Forde, Darragh G McArt, et al.
Cancer Science|April 14, 2010
Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cellsMohamed K El-Tanani, Hiu-Fung Yuen, Zhanzhong Shi, et al.
Oncotarget|December 15, 2015
Molecular classification of non-invasive breast lesions for personalised therapy and chemopreventionNiamh Buckley, David Boyle, Darragh McArt, et al.
Computational and Structural Biotechnology Journal|July 14, 2022
A bespoke target selection tool to guide biomarker discovery in tubo-ovarian cancerJames P Beirne, Alan Gilmore, Caitríona E McInerney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapyJennifer E Quinn, Colin R James, Gail E Stewart, et al.
The Journal of Biological Chemistry|May 16, 2002
BRCA1 regulates the interferon gamma-mediated apoptotic responseHeather N Andrews, Paul B Mullan, Stewart McWilliams, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Oncogene|June 9, 2005
The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-gamma-mediated apoptosisPaul B Mullan, Alison M Hosey, Niamh E Buckley, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2019
Identification and SAR exploration of a novel series of Legumain inhibitorsSharon L Eddie, Aaron Gregson, Emma Graham, et al.
Molecular Cancer Research : MCR|March 22, 2007
BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNsNiamh E Buckley, Alison M Hosey, Julia J Gorski, et al.
Cancer Research|March 11, 2010
BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcriptionMary T Harte, Garrett J O'Brien, Niamh M Ryan, et al.
Scientific Reports|March 22, 2016
Quantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatmentNiamh E Buckley, Claire Forde, Darragh G McArt, et al.
Cancer Science|April 14, 2010
Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cellsMohamed K El-Tanani, Hiu-Fung Yuen, Zhanzhong Shi, et al.
Oncotarget|December 15, 2015
Molecular classification of non-invasive breast lesions for personalised therapy and chemopreventionNiamh Buckley, David Boyle, Darragh McArt, et al.
Computational and Structural Biotechnology Journal|July 14, 2022
A bespoke target selection tool to guide biomarker discovery in tubo-ovarian cancerJames P Beirne, Alan Gilmore, Caitríona E McInerney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapyJennifer E Quinn, Colin R James, Gail E Stewart, et al.
The Journal of Biological Chemistry|May 16, 2002
BRCA1 regulates the interferon gamma-mediated apoptotic responseHeather N Andrews, Paul B Mullan, Stewart McWilliams, et al.
Pageof 4